Trana Discovery

Trana Discovery is a privately held, pre-revenue platform company specializing in infectious disease drug discovery. Its core asset is a patented screening technology that identifies compounds which inhibit pathogen-specific tRNA, a novel mechanism of action intended to overcome antimicrobial resistance. The company operates with a lean, virtual team of industry veterans and seeks partnerships to advance drug discovery programs in human and agricultural health. Its focus addresses the critical global need for new antibiotics and antivirals.

Proprietary screening platform that identifies compounds which bind to the anti-codon stem loop (ASL) of pathogen-specific transfer RNA (tRNA), inhibiting replication. Applicable to bacterial, viral, and fungal targets.

Competes with numerous other drug discovery platform companies and novel mechanism approaches (e.g., phage therapy, antimicrobial peptides, virulence factor inhibition). Success depends on demonstrating superior hit rates or lead quality compared to established high-throughput screening methods.